Atorlip 5: Effective LDL Cholesterol Management for Cardiovascular Health
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.62 | $36.98 (0%) | 🛒 Add to cart |
| 90 | $0.52 | $55.47 $46.44 (16%) | 🛒 Add to cart |
| 120 | $0.47 | $73.96 $56.76 (23%) | 🛒 Add to cart |
| 180 | $0.42 | $110.94 $75.68 (32%) | 🛒 Add to cart |
| 270 | $0.39 | $166.41 $105.78 (36%) | 🛒 Add to cart |
| 360 | $0.38
Best per pill | $221.88 $135.02 (39%) | 🛒 Add to cart |
Similar products
Atorlip 5 contains atorvastatin calcium, a potent HMG-CoA reductase inhibitor specifically formulated to reduce elevated levels of low-density lipoprotein (LDL) cholesterol and triglycerides in the blood. By competitively inhibiting the enzyme responsible for cholesterol synthesis in the liver, this medication supports the achievement of target lipid levels as established by current clinical guidelines. It is indicated as an adjunct to diet and other lifestyle measures for patients requiring pharmacological intervention to mitigate cardiovascular risk. Proper usage under medical supervision can significantly contribute to long-term vascular health.
Features
- Active ingredient: Atorvastatin calcium 5 mg
- Pharmaceutical form: Film-coated tablets
- Mechanism: Selective, competitive inhibition of HMG-CoA reductase
- Bioavailability: Approximately 12%
- Plasma protein binding: ≥98%
- Metabolism: Primarily hepatic via CYP3A4
- Elimination half-life: Approximately 14 hours
- Excretion: Primarily via bile; minimal renal excretion
Benefits
- Significantly reduces LDL cholesterol levels, directly addressing a major modifiable risk factor for atherosclerosis
- Lowers triglyceride concentrations and modestly increases high-density lipoprotein (HDL) cholesterol
- Contributes to stabilization of existing atherosclerotic plaques, reducing the risk of rupture and subsequent thrombotic events
- Demonstrates proven efficacy in primary and secondary prevention of cardiovascular events
- Supports long-term management of dyslipidemia with a well-tolerated dosing profile
- Offers flexibility in dosing titration based on individual patient response and tolerance
Common use
Atorlip 5 is prescribed for patients with primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and mixed dyslipidemia. It is utilized when dietary modifications and other non-pharmacological approaches prove insufficient to achieve target lipid levels. The medication is also indicated to reduce cardiovascular risk in patients with multiple risk factors, even when baseline cholesterol levels are only moderately elevated. Clinical use extends to patients with established cardiovascular disease for secondary prevention.
Dosage and direction
The recommended starting dose is 5 mg or 10 mg once daily, with dosage adjustments made at intervals of 2-4 weeks based on lipid response. Administration may occur at any time of day, with or without food, though consistency in timing is advised. The maximum daily dose should not exceed 80 mg except in rare circumstances under close supervision. Liver function tests must be performed before initiation and periodically thereafter. Dose adjustments may be necessary for patients taking concomitant medications that inhibit CYP3A4.
Precautions
Liver function should be monitored before treatment initiation and periodically thereafter. Patients should report any unexplained muscle pain, tenderness, or weakness promptly. Use with caution in patients consuming substantial quantities of alcohol or with a history of liver disease. Blood glucose levels should be monitored as statins may increase hemoglobin A1c and fasting serum glucose levels. Temporary discontinuation may be necessary in patients experiencing severe metabolic or endocrine disorders, major surgery, trauma, or severe acute infection.
Contraindications
Active liver disease or unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal. Hypersensitivity to any component of this medication. Pregnancy, lactation, and women of childbearing potential not using adequate contraception. Concomitant use with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, HIV protease inhibitors, or clarithromycin. Severe renal impairment (creatinine clearance <30 mL/min).
Possible side effects
Common adverse reactions (≥1/100 to <1/10) include headache, insomnia, nausea, diarrhea, dyspepsia, arthralgia, and myalgia. Uncommon side effects (≥1/1,000 to <1/100) may include constipation, flatulence, dizziness, rash, pruritus, and asthenia. Rare but serious adverse events include rhabdomyolysis with renal dysfunction, hepatitis, pancreatitis, and peripheral neuropathy. Elevated liver enzymes occur in approximately 0.7% of patients, typically reversible upon discontinuation.
Drug interaction
Potent CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors) significantly increase atorvastatin exposure. Cyclosporine, gemfibrozil, and niacin may increase the risk of myopathy. Concurrent use with warfarin may potentiate anticoagulant effect requiring INR monitoring. Oral contraceptives containing norethindrone and ethinyl estradiol show increased AUC. Colchicine coadministration may increase risk of myopathy. Calcium channel blockers (verapamil, diltiazem) may moderately increase atorvastatin concentrations.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one. Consistency in daily administration is important for maintaining stable lipid-lowering effects.
Overdose
There is no specific antidote for atorvastatin overdose. Supportive measures should be implemented with attention to liver function and possible rhabdomyolysis. Gastric lavage may be considered if presented soon after ingestion. Liver enzymes and CPK levels should be monitored closely. Hemodialysis is not expected to significantly enhance elimination due to extensive protein binding.
Storage
Store at room temperature (15-30°C) in the original container protected from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging. Tablets should not be removed from blister strips until immediately before administration to maintain stability.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions must be made by qualified healthcare professionals based on individual patient circumstances. Patients should not initiate, modify, or discontinue medication without consulting their physician. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions.
Reviews
Clinical trials demonstrate that atorvastatin 5 mg produces mean LDL-C reductions of approximately 30-39% from baseline. The ASTEROID trial showed regression of coronary atherosclerosis with intensive statin therapy. The SPARCL trial established benefit in stroke reduction post-cerebrovascular event. Real-world evidence supports the cardiovascular risk reduction benefits observed in randomized controlled trials, with particular efficacy in elderly patients and those with diabetes. Patient satisfaction surveys indicate good tolerability profile with maintenance of quality of life measures.